Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases: A Single-Center, Single-Arm, Open-Label Clinical Study (PRICE)

This study attempts to employ a combination therapy using rhG-CSF, IL-2, and PD-1 inhibitors, aiming to overcome the limitations of monotherapy in immunotherapy through multi-faceted immune regulation. By modulating the immune microenvironment to enhance immune cell infiltration, and breaking through the physical and immunosuppressive barriers of tumors, it seeks to augment the efficacy of immunotherapy. This approach explores the effectiveness of a neoadjuvant treatment model in cases of liver metastasis.

开始日期2024-07-10

申办/合作机构

南京医科大学第三附属医院

EUCTR2019-001696-36-IT / Not yet recruiting临床2期IIT

Study of efficacy of low-dose recombinant human interleukin-2 in immunological changes associated with depression (IL2REG) - IL2REG

开始日期2019-10-09

申办/合作机构

Ospedale San Raffaele Srl

NCT02467504 / Completed临床2期IIT

A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Methotrexate (MTX)-Naive Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease, characterized by symmetric poly-arthritis usually involving the small joints of the hands and feet. In addition, various extra-joint manifestations may develop. Several immunomodulating agents have been attempted in the treatment of RA without achieving satisfactory results. Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune diseases, which can be promoted by interleukin-2 (IL-2). The investigators hypothesized that low-dose IL-2 could be a novel therapy in active RA patients. This clinical study will test the efficacy and safety of low dose IL-2 treatment in RA. The investigators perform a single-centre, double-blind pilot trial with hrIL-2 in RA. The investigators evaluate the effectiveness and safeness of low-dose hrIL-2 for RA by randomized controlled study (hrIL-2 (N = 23) + Methotrexate (MTX)+ Loxoprofen versus placebo+MTX + Loxoprofen group (N = 24)).

开始日期2015-07-01

申办/合作机构

北京大学人民医院

[+2]

100 项与重组人白介素-2 (北京双鹭药业) 相关的临床结果

登录后查看更多信息

100 项与重组人白介素-2 (北京双鹭药业) 相关的转化医学

登录后查看更多信息

100 项与重组人白介素-2 (北京双鹭药业) 相关的专利（医药）

登录后查看更多信息

100 项与重组人白介素-2 (北京双鹭药业) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AC01	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肿瘤	中国	北京双鹭药业股份有限公司	1999-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性干燥综合征	药物发现	中国	北京双鹭药业股份有限公司	2015-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02467504 (CTgov)	临床2期	类风湿关节炎	47	Loxoprofen+Folic Acid+MTX+hrIL-2 active (Experimental)	廠築鹽網鏇願憲構鹽襯(鏇遞鹽選鏇餘築窪襯積) = 顧鬱製構願齋夢壓鑰淵築積選鬱繭範夢選遞窪 (憲製襯餘簾醖構鹹繭艱, 製範夢衊製觸衊廠獵積 ~ 醖糧範襯繭餘廠餘壓廠) 更多	-	2019-09-09
				hrIL-2 placebo+Loxoprofen+Folic Acid+MTX (Placebo Comparator)	廠築鹽網鏇願憲構鹽襯(鏇遞鹽選鏇餘築窪襯積) = 壓齋築選積遞簾鏇顧製築積選鬱繭範夢選遞窪 (憲製襯餘簾醖構鹹繭艱, 蓋繭艱簾遞製衊鑰齋繭 ~ 繭餘艱鑰艱遞製製願鏇) 更多